INTRODUCTION
The transforming growth factor-b (TGFb) family of cytokines play central roles in many aspects of metazoan embryonic development and tissue homeostasis Shen and Schier, 2000; Sporn and Roberts, 1990) . TGFb family members bind two types of membrane serine/threonine kinases, the type I and type II receptors, forming a heteromeric receptor complex. The type II receptor then phosphorylates and activates the type I receptor, which in turn phosphorylates Smad transcription factors (Shi and Massagué , 2003) . Of the eight Smad family members in human, five function as receptor substrates (RSmads). Smad2 and Smad3 do so as substrates of TGFb, nodal and activin receptors, and Smads 1, 5, and 8 as substrates of the receptors for bone morphogenetic proteins, myostatin and anti-muellerian hormone. Receptor-mediated phosphorylation triggers nuclear accumulation of RSmads and their binding to Smad4. Smad4, itself not a receptor substrate, is an essential partner of RSmads in transcriptional regulation of many genes. RSmad-Smad4 complexes bind a diverse group of DNA binding factors to achieve target gene selection and recruit transcriptional coactivators or corepressors for gene regulation (Feng and Derynck, 2005; Massagué et al., 2005) . This general mechanism underlies a large number of TGFb gene responses controlling cell proliferation, organization, and fate.
Smad proteins consist of a conserved N-terminal DNA binding domain (or MH1 domain) containing a DNA binding site, a variable linker region, and a C-terminal MH2 domain. At different steps during signal transduction, the MH2 domain binds cytoplasmic anchor proteins, TGFb receptors, partner Smads, nucleoporins, DNA binding cofactors, or transcriptional coregulators (Massagué et al., 2005) . Receptor-mediated phosphorylation occurs at two serine residues in the extreme C-terminal sequence Ser-Val-Ser (Ser-Met-Ser in Smad2) of RSmads. This creates an acidic tail that binds to a basic pocket in the Smad4 MH2 domain, forming the RSmad-Smad4 complex (Wu et al., 2001) .
A decade-long focus on the central role of Smad4 as a shared partner of all RSmads and a mediator of many TGFb effects has sidestepped the possibility of alternative RSmads partners. However, evidence from Smad4-deficient organisms and tumor cell lines indicates that Smad4 is not required for all the actions of the TGFb family (Sirard et al., 1998; Subramanian et al., 2004; Wisotzkey et al., 1998) . TGFb may also signal via MAPK and PI3K kinases, PP2A phosphatases, and Rho family members (Derynck and Zhang, 2003; Massagué , 2000) . Yet, signaling via RSmads independently of Smad4 remains possible, as suggested by the more severe phenotype of mad (Smad1) mutants compared to medea (Smad4) mutants in Drosophila (Wisotzkey et al., 1998) , by differences in the phenotype of Smad2 null and Smad4 null mice (Sirard et al., 1998) , and by the prominent presence of phospho-Smad2/3 in Smad4-defective pancreatic cancer cells (Subramanian et al., 2004) .
Here we report the identification of TIF1g (also known as TRIM33, RFG7, PTC7, and Ectodermin) as a protein that selectively binds receptor-activated Smads 2 and 3. Four TIF1 family members (a to d) are known in mammals, and orthologs are present in organisms through Drosophila (Beckstead et al., 2001; Friedman et al., 1996; Khetchoumian et al., 2004; Le Douarin et al., 1996; Moosmann et al., 1996) . TIF1a binds nuclear hormone receptors and functions as a coactivator of retinoic acid receptor . TIF1b is an intrinsic component of the histone deacetylase N-CoR1/HDAC3 complex (Underhill et al., 2000) and functions as a corepressor for Krü ppelassociated box (KRAB) zinc-finger transcription factors (Friedman et al., 1996; Moosmann et al., 1996; Schultz et al., 2001 ) and a cofactor for HP1 proteins in heterochromatin-mediated gene silencing . TIF1g is not known to have any of these functions. Cued by the observation that the TIF1g homolog in the zebrafish is essential for blood formation (Ransom et al., 2004) , we investigated the role of TIF1g in the TGFb response of human hematopoietic progenitor cells (Ohta et al., 1987) .
We found that in these cells, Smad4 mediates growth inhibition whereas TIF1g mediates erythroid differentiation in response to TGFb, thus establishing separate effector functions for these two branches of the Smad pathway.
RESULTS

Identification of TIF1g as a Smad2/3 Binding Protein
We developed an affinity-purification strategy to isolate proteins that selectively bind to activated RSmads. Mutant forms of Smad1, Smad2, and Smad3 were created in which the C-terminal Ser residues at the À1 and À3 positions were mutated to Asp (S2D mutants). X-ray crystal structure analysis and biochemical studies have shown that these mutations mimic the receptor-phosphorylated pSer-Xxx-pSer Smad C-terminal motif in driving RSmadSmad4 complex formation (Chacko et al., 2004; Qin et al., 2001; Wu et al., 2001) . Recombinant glutathione-S-transferase (GST) fusion proteins containing the linker and MH2 (L+MH2) region of either wild-type RSmads or S2D mutants ( Figure 1A ) were immobilized and used in large-scale affinity purification of human HeLa cell extracts. A reproducible pattern of eluted proteins was detected by Coomassie staining of eluates from GSTSmad2(L+MH2) ( Figure 1B) . A similar pattern was obtained with GST-Smad3(L+MH2) as the bait (data not shown), as may be expected from the similarity (91% sequence identity) between the L+MH2 regions of Smad2 and Smad3. Very few protein bands could be visualized (A) Scheme of GST-tagged linker (L) and MH2 region of Smad2 and its phosphorylation-site mutants. Two C-terminal Ser (S) residues were mutated to Asp residues (marked in red) to mimic receptor-mediated phosphorylation. (B and C) HeLa cell extracts were subjected to affinity purification with the indicated baits. Eluted proteins were resolved on SDS-PAGE and stained with Coomassie blue. Bands were excised and identified by mass spectrometry analysis. (D and E) COS-1 cells were transfected with vectors encoding TIF1g, Smad2, Smad3, or Smad4 in the presence of constitutively active [TbRI(AAD)] or kinase-dead [TbRI(K-R)] TGFb type I receptor constructs, as indicated. Lysates were immunoprecipitated (IP) and subsequently immunoblotted (IB) with antibodies indicated on the left. Protein expression was monitored by immunoblot analysis of total cell extracts (Input).
when using either wild-type or S2D mutant forms of GSTSmad1(L+MH2) as the bait (data not shown).
As identified by mass spectrometry, the proteins that bound equally well to wild-type and S2D Smad2/3 baits included the transcriptional coactivator CBP, which is known to bind RSmads (Massagué et al., 2005) ; BRG1, BAF155, BAF170, and OSA2, which are subunits of SWI/SNF chromatin remodeling complexes (Narlikar et al., 2002; Roberts and Orkin, 2004) previously unknown to interact with Smads; and the transcriptional coactivator NCoA3 (Spiegelman and Heinrich, 2004) . A 140 kDa protein identified as TIF1g drew our attention because it bound several-fold more abundantly to Smad2(L+MH2)(S2D) than to the wild-type bait ( Figure 1B ). TIF1g was also present in eluates from the Smad3(L+MH2)(S2D) column (data not shown). Of the four known mammalian TIF1 family members, only TIF1g was isolated under these conditions. The molecular size of the L+MH2 baits is close to that of Smad4 and would obscure Smad4 on SDS-PAGE of the eluates. Smad4 was identified by mass spectrometry analysis in the eluate from a bait of smaller size, Smad2 MH2(S2D) ( Figure 1C) . No other components were identified that bound preferentially to the wild-type or (S2D) baits.
TIF1g Selectively Binds Activated Smad2/3
To determine whether Smads 2 and 3 bind to TIF1g in vivo, and whether this interaction is stimulated by TGFb receptor signaling, we transfected COS-1 cells with vectors encoding Flag-tagged TIF1g, HA-tagged Smad2 or Smad3, and a constitutively active mutant form of type I TGFb receptor, TbRI(AAD) (Chen et al., 1998) , or a kinase-inactive mutant, TbRI(KR) (Wrana et al., 1994) (Figure 1D ). TIF1g complexes with both Smad2 ( Figure 1D , left panel) and Smad3 ( Figure 1D , right panel) could be coimmunoprecipitated from these cells, and this interaction was stimulated by the activated receptor. In similar experiments using HA-tagged Smad4, only a trace amount of the overexpressed protein could be coimmunoprecipitated with TIF1g, and this was not increased by the activated receptor (data not shown).
To directly compare the affinity of TIF1g for different Smad proteins, we cotransfected cells with vectors encoding TIF1g, activated receptor, Smad2, and either Smad3 or Smad4 ( Figure 1E ). Equivalent amounts of Smad2 and Smad3 could be coimmunoprecipitated with TIF1g ( Figure 1E , left panel). In contrast, in cells expressing similar levels of exogenous Smad2 and Smad4, a very small amount of Smad4 compared to Smad2 was coimmunoprecipitated with TIF1g ( Figure 1E , right panel). These results indicated that TIF1g has high affinity for activated Smads 2 and 3.
TIF1g and Smad2/3 Interaction Domains TIF1a and TIF1b tested under the same conditions as TIF1g failed to bind Smad2 (Figure 2A ). TIF1 family members share sequence similarity within the RBCC (Ring finger-B boxes-Coiled Coil) and PHD/bromodomain regions (PB) but are quite divergent in the middle region (M) linking these domains (Figure 2A ). Indeed, domain deletion experiments mapped the Smad binding region to the middle region of TIF1g ( Figure 2B ). Recombinant portions of these proteins were made in bacteria as fusion products, purified, and tested for binding in vitro. A MBP (maltose binding protein) fusion protein containing the linker and MH2 domain of Smad2 [MBP-Smad2(L+MH2)] was able to bind a GST fusion with the middle region and PHD/bromodomain of TIF1g but not a GST fusion with only the PHD/bromodomain region ( Figure 2C ). The version MBP-Smad2(L+MH2)(S2D), containing C-terminal acidic mutations, showed a higher affinity for TIF1g in vitro ( Figure 2C ). When overexpressed in cells, the middle region of TIF1g inhibited the Smad2/3-Smad4 interaction ( Figure 2D ), suggesting competition (see below). These results argue that the activated MH2 domain in Smads 2 and 3 specifically and selectively binds to the middle region of TIF1g through direct interactions ( Figure 2E ).
Coexistence of Smad2/3-TIF1g and Smad2/3-Smad4 Complexes We raised anti-TIF1g polyclonal antibodies that recognize the endogenous protein by immunoblotting, immunoprecipitation and cell immunofluorescence. TIF1g mRNA is expressed in many tissues (Venturini et al., 1999) . Accordingly, we detected TIF1g in all cell types tested, including primary human hematopoietic progenitors, mouse embryo fibroblasts, and mouse T cells, as well as cell lines derived from normal tissues and tumors ( Figure 3 and data not shown). Immunofluorescence staining using affinity-purified anti-TIF1g antibodies revealed that TIF1g is localized in the nucleus, outside of nucleoli, in HaCaT human keratinocytes and all other cell types tested ( Figure 3A , and data not shown). A punctate pattern coexisted with a more diffuse nuclear distribution, all of which was specific as shown by loss of the signal upon depletion of TIF1g by means of a short-hairpin RNA (shRNA) (Figure 3A) . A punctate TIF1g nuclear pattern has also been noted by others (Ransom et al., 2004) .
Importantly, TGFb addition induced the formation of an endogenous Smad2/3-TIF1g along with a Smad2/3-Smad4 complex ( Figure 3B ). Formation of both complexes was entirely dependent on TGFb addition. The relative abundance of these two complexes was proportional to the relative abundance of TIF1g and Smad4. Thus, primary mouse embryo fibroblasts, human M091 acute myelogenous leukemia ( Figure 3B ), and mouse T lymphocytes (data not shown) revealed abundant Smad2/3-TIF1g and Smad2/3-Smad4 complexes in response to TGFb, whereas the Smad2/3-TIF1g complex was less abundant in HaCaT keratinocytes and other cell lines that express high levels of Smad4 relative to TIF1g ( Figure 3C , and data not shown). The Smad2/3-TIF1g complex was more abundant in the Smad4-defective tumor cell lines MDA-MB-468 ( Figure 3C ), SW480 ( Figure 3E ), and BxPC3 ( Figure S1A ).
Formation of a TGFb-dependent Smad2/3-TIF1g complex was also demonstrated by anti-Smad2/3 immunoblotting of anti-TIF1g immunoprecipitates ( Figure S1A ).
In order to compare the relative contribution of endogenous Smad2 and Smad3 to the formation of TIF1g complexes, we decreased the level of endogenous Smads 2 or 3 using specific shRNAs. The results show that both Smad2 and Smad3 contribute to the formation of complexes with TIF1g ( Figure S1B ).
TIF1g and Smad4 Competitively Share Smad2/3
Quantitation by immunoblotting using recombinant proteins as standards indicated a content of 0.1 pmol of TIF1g, 1.4 pmol of Smad4, and 0.6 pmol of Smad2 per 10 6 HaCaT cells (data not shown). The higher abundance of Smad4 over TIF1g may explain, at least partly, the prevalence of the Smad2/3-Smad4 complex over Smad2/3-TIF1g complex. Forced overexpression of Smad4 inhibited the formation of the Smad2/3-TIF1g complex to near completion ( Figure 3D ). Conversely, TIF1g overexpression inhibited the Smad2/3-Smad4 interaction (Figures 3E, left panel, and 2D) . HaCaT cells formed more Smad2/3-TIF1g complex when Smad4 was depleted using a specific shRNA ( Figure 3E , central panel). Furthermore, formation of an endogenous Smad2/3-TIF1g complex in the Smad4-defective cell line SW480 was inhibited by restoration of Smad4 expression, whereas a truncated Smad4 construct [Smad4(1-363)] that does not bind Smad2/3 (Hata et al., 1997) lacked this effect ( Figure 3E , right panel). These results suggest that Smad4 and TIF1g competitively share the pool of TGFb-activated Smad2/3. Xenopus TIF1g, which is called ectodermin, was recently suggested to act as a general inhibitor of TGFb (C) Purified maltose binding protein (MBP) Smad fusion products were prebound to amylose beads and mixed with purified GST-tagged TIF1g protein domains. MBP-tagged proteins bound to the beads were detected by Coomassie blue staining. GST-tagged proteins were detected by Western immunoblotting using anti-GST antibodies. (D) HEK293 Cells were transfected with vectors encoding TIF1g or TIF1g fragments and receptor constructs, as indicated. Endogenous Smad2 was immunoprecipitated, and the precipitates were immunoblotted as indicated. (E) Scheme of Smad2-and TIF1g-interacting domains. The location of truncating mutations in zebrafish TIF1g (Ransom et al., 2004 ) is indicated by arrowheads.
and BMP signaling by binding to Smad4 and causing Smad4 ubiquitination and degradation (Dupont et al., 2005) . However, we observed that TIF1g has a strong binding preference for Smad2/3 over Smad4 ( Figures 1E  and 3D ); TIF1g overexpression did not cause a decrease in the level of endogenous Smad4 ( Figures 2D and 3E , left panel); TIF1g overexpression did not cause Smad4 ubiquitination under conditions in which Smad2 was polyubiquinated by the Smad ubiquitin ligase Smurf2 ( Figure S1C ). Depletion of endogenous TIF1g by shRNA did not affect the rate of Smad2 phosphorylation or dephosphorylation after TGFb stimulation, or the level of endogenous Smad4 ( Figure S1D ).
Mild Inhibition of Smad4-Dependent Gene Responses by TIF1g
We tested the ability of TIF1g to affect various TGFb gene responses that depend on Smad4. These genes include plasminogen activator inhibitor-1 (PAI-1), JUNB, and CDKN1A encoding the CDK inhibitor p21Cip1/WAF. Ectopic overexpression of TIF1g in HaCaT cells partially inhibited the induction of PAI-1 and CDKN1A by TGFb (Figures 3F and S2A) . In complementary experiments, MDA-MB-231 cells subjected to depletion of endogenous TIF1g by shRNA ( Figure 3G ) showed a mild enhancement in the induction of CDKN1A and JUNB by TGFb ( Figures  3H and S2B ). These results argue that TIF1g is neither a mediator nor a potent inhibitor of Smad4-dependent TGFb gene responses.
Role of TIF1g in Human Erythropoiesis
The closest homolog of TIF1g in the zebrafish is encoded by moonshine (mon), an essential gene in blood formation (Ransom et al., 2004) . The most carboxy-terminal mutation reported in mon spares the RBCC domain but truncates the middle region, which corresponds to the Smad-interacting domain of TIF1g (refer to Figure 2E ). Based on these clues, we investigated the possible role of TIF1g in mammalian hematopoietic cells and their response to TGFb.
Immunohistochemical analysis of mouse embryo sections revealed a widespread pattern of TIF1g expression with nuclear staining of most tissues throughout gestation ( Figure 4A for E12.5; data not shown for other stages). TIF1g immunostaining was particularly pronounced in round hematopoietic cells in yolk sac blood islands in E8.5 embryos ( Figure 4B, top) , which are sites of primitive hematopoiesis. Interestingly, these hematopoietic cells were also strongly stained by anti-phospho-Smad2 antibodies ( Figure 4B, middle) , suggesting an important role of TGFb in hematopoiesis. Only weak staining of hematopoietic cells was observed in blood islands from antiphospho-smad3 antibodies ( Figure 4B, bottom) , which may reflect a low total Smad3 expression level. Strong nuclear staining was also observed in CD34 + hematopoietic stem/progenitor cells isolated from human umbilical cord blood ( Figure 4C ). To investigate the role of TIF1g in hematopoietic development, human umbilical cord blood was utilized as a source of CD34 + hematopoietic stem/progenitor cells (Cohen and Nagler, 2004; Shizuru et al., 2005) . These cells were infected with retroviruses encoding TIF1g shRNA, followed by selection of the transduced cell population. This achieved a 70% drop in endogenous TIF1g mRNA level, as determined using quantitative RT-PCR (data not shown). Cells were then assayed for proliferation and differentiation in several well-established assay systems ( Figure 5A ). When placed in methylcellulose semi-solid medium with stem cell factor (SCF), interleukin-3 (IL-3), and erythropoietin (EPO) as a differentiation factor, CD34 + hematopoietic progenitors form burst colonies that progressively differentiate into erythrocytes in two weeks. In this colonyforming assay, the knockdown of TIF1g did not have a major effect on the number of burst-forming units-erythoid (BFU-E) ( Figure 5B , top) or size distribution of the colonies (Table S1 ). However, the BFU-E colonies formed by TIF1g-depleted cells were less differentiated, as determined by cytospin of plucked colonies examined for differentiation ( Figure 5C ). Compared to 2 week control cultures, which already had a large proportion of cells in the final stages of erythroid differentiation, the TIF1g-depleted cultures showed a shift toward earlier stages of differentiation ( Figure 5C ). In secondary passages of these colonies (refer to Figure 5A ), the control cultures formed very few erythroid colonies, indicating that the majority of cells in these cultures had already entered the late differentiation stages ( Figure 5B , bottom). TIF1g depletion increased secondary erythroid colony formation, including large multifocal BFU-E, 7-fold compared to control transduced cells ( Figure 5B , bottom). Depletion of Smad2 or Smad3 resulted in small increases in secondary colony formation, and depletion of Smad4 had no effect. Collectively, these results argue that TIF1g promotes hematopoietic stem/progenitor cell differentiation along the erythroid lineage at the expense of expansion of the early BFU-E stages.
Distinct Roles of TIF1g and Smad4 in TGFb Action
Culture in liquid media containing SCF, thrombopoietin (TPO), and Flt3 ligand (FL) has been shown to stimulate the proliferation of CD34 + hematopoietic stem/progenitor cells. TGFb addition profoundly inhibited cell proliferation under these conditions ( Figure 5D ). TIF1g knockdown did not protect against this effect whereas Smad4 knockdown blunted the growth-inhibitory action of TGFb ( Figure 5D ). Smad2 and Smad3 knockdown also significantly blunted the growth-inhibitory action of TGFb ( Figure 5D ). These results suggest that Smad2 and Smad3 together with Smad4, but not TIF1g, mediate the growth-inhibitory response to TGFb in hematopoietic stem/progenitor cells. To analyze effects on erythroid differentiation, we placed control or knockdown CD34 + hematopoietic stem/progenitor cells in liquid media containing EPO and SCF. Three days after sorting, most of the cells were still in the early stages of differentiation (i.e., proerythroblast and basophilic erythroblast stages) (Figures 6A and 6C ). Knockdown of TIF1g or Smads 2, 3, or 4 had little effect on the differentiation state of these cells at this early stage, although a trend toward differentiation was apparent in Smad4 knockdown cells and an opposite trend in the other knockdown cells ( Figure 6C ). Addition of TGFb at the start of the 3 day incubation markedly accelerated the differentiation of hematopoietic stem/progenitor cells into erythrocytes and concurrently inhibited cell proliferation ( Figures 6A-6E ). Note that erythrocytes forming after 3 days in these assays would have originated from progenitors (CFU-E) committing to differentiation on the first day in culture. Therefore, effects on cell differentiation would correspond to changes in the rate of differentiation of committed progenitors, whereas effects on cell proliferation would correspond to changes in cells that remain in the progenitor state for most of the 3 day incubation. Smad4 knockdown blunted the growth-inhibitory effect of TGFb but did not diminish the TGFb-dependent accumulation of erythrocytes ( Figures 6C and 6D ). In contrast, TIF1g knockdown with two different shRNAs strongly inhibited the TGFb-dependent accumulation of erythrocytes but did not diminish the growth-inhibitory effect of TGFb ( Figures 6A and 6B ). Knockdown of Smad2 or Smad3 decreased both the TGFb-dependent accumulation of erythrocytes and the growth-inhibitory effect ( Figures  6C and 6D ). Addition of a TGFb type I receptor kinase inhibitor SB431542 (Laping et al., 2002) as a blocker of autocrine TGFb caused a trend toward less differentiation and blocked the effect of exogenous TGFb (data not shown).
Smad2/3-TIF1g Interaction in TGFb-Dependent Erythroid Differentiation
To test the role of the Smad-TIF1g interaction in erythroid differentiation we used constructs encoding the Smad2/3-interacting middle region of TIF1g. Trimming of the N-terminal or C-terminal portions of the middle region abolished its ability to bind Smad2 in transfected cells ( Figure 7A ). Therefore, the entire middle region is required for this interaction. CD34 + hematopoietic stem/progenitor cells were transfected with a vector encoding the TIF1g middle region. The cultures were maintained in the presence of TGFb for 4 days in order to allow the accumulation of erythrocytes. Overexpression of the TIF1g middle region, which served as a potential dominant-negative mutant, indeed inhibited the effect of TGFb on erythroid differentiation ( Figure 7B) . A construct encoding the middle region with a small C-terminal deletion (M-del3 construct), which fails to bind Smad2 ( Figure 7A ), did not inhibit TGFb-induced differentiation ( Figure 7B ). This suggests that the TIF1g middle region also recognizes Smads in CD34 + cells. To further test the requirement of the Smad2/3-TIF1g interaction in TGFb-dependent erythroid differentiation, we checked the ability of Smad binding defective and wildtype TIF1g constructs to rescue TGFb-dependent erythroid differentiation in TIF1g-depleted CD34 + hematopoietic stem/progenitor cells ( Figure 7C ). We created a sh(TIF1g)-resistant version of TIF1g (rTIF1g) by introducing silent mutations into the cDNA region that is targeted by the sh(TIF1g). We then used this construct to create chimeras in which the Smad binding middle region of TIF1g was replaced with the nonbinding middle region of TIF1a or TIF1b (rTIF1g/a and rTIF1g/b constructs; Figure 7C ).
The expression level of these chimeras in transfected HEK293 cells was equal to or higher than that of the wildtype TIF1g (data not shown). These constructs were engineered into an IRES green fluorescent protein vector and the sh(TIF1g) into a yellow fluorescent protein vector, in order to allow sorting of doubly transfected cells. In 4 day differentiation assays in the presence of TGFb, sh(TIF1g)-transfected CD34 + cells showed a diminished erythroid maturation compared to control transfectants ( Figure 7C ). Cotransfection of rTIF1g rescued the ability of TGFb to stimulate erythroid differentiation in sh(TIF1g)-transfected CD34 + cells, providing further evidence of the specificity of this sh(TIF1g) vector. More importantly, cotransfection of the rTIF1g/a or rTIF1g/b constructs did not reverse the effect of sh(TIF1g) on TGFb-induced differentiation ( Figure 7C ). We conclude that the Smad2/3-TIF1g-interacting region is important for TIF1g to mediate the effect of TGFb on erythroid differentiation. Although the only known function of this region is to bind Smad2/3, we cannot exclude the possibility that another protein might bind to this same region and mediate the TGFb effect.
DISCUSSION
Novel Smad Interactions C-terminal phosphorylation of RSmad proteins by TGFb receptor kinases is a critical event in signal transduction because it creates a docking site for Smad4 allowing the assembly of signaling complexes (Shi and Massagué , 2003) . Smad4 was the only factor known to occupy this key position in the pathway. Searching for new partners of activated Smads, we have identified TIF1g as an alternative effector of TGFb-activated Smad2/3. TIF1g is a nuclear protein expressed in most tissues during mouse embryo development and in the adult. TIF1g competitively shares Smad2/3 with Smad4, mediating signaling functions that are distinct from those of the classical Smad2/ 3-Smad4 complex ( Figure 7E ). We show a TGFb-dependent interaction between endogenous Smad2/3 and TIF1g alongside the Smad2/3-Smad4 interaction in different mammalian cell types. Thus, TIF1g could play a role in TGFb signaling in different contexts. TIF1g and Smad4 were the only proteins from HeLa cell extracts that preferentially bound to activated Smad2/3 in protein affinity-chromatography experiments. Smad2/3 binding maps to the region of TIF1g linking the RBCC domain and the PHD/bromodomain. This region is poorly conserved in TIF1a and TIF1b, which do not bind Smad2/ 3. Our protein purification approach also yielded a class of proteins that bind equally well to the basal and activated forms of Smads 2 and 3. These proteins include the transcriptional coactivators CBP and NCoA3 (Spiegelman and Heinrich, 2004) and several subunits of the SWI/SNF ATP-dependent nucleosome remodeling complex (Narlikar et al., 2002; Roberts and Orkin, 2004) . The important role of CBP as a transactivation cofactor of RSmads is well established (Feng and Derynck, 2005; Massagué et al., 2005) . The previously unknown ability of Smad2/3 to interact with SWI/SNF components and NCoA3 suggests a larger role of Smad proteins in chromatin remodeling than previously appreciated.
A TGFb-Dependent Smad2/3-TIF1g Complex Formation of an endogenous Smad2/3-TIF1g complex is strictly dependent on TGFb stimulation. In vitro, however, TIF1g can bind to the basal-state Smad2 and Smad3 MH2 domains, albeit less avidly than it binds to these proteins in the activated state. Thus, TIF1g may recognize the C-terminal motif pSer-Met/Val-pSer (or its mimic Asp-Met/ Val-Asp) in the context of other contacts with the MH2 domain. These properties are also characteristic of the Smad2/3-Smad4 interaction (Shi and Massagué , 2003) . Consistent with these similarities, we find that TIF1g and Smad4 competitively share the pool of activated Smad2/ 3 in TGFb-stimulated cells. The relative abundance of these two complexes depends on the relative abundance of TIF1g and Smad4 in a cell. Overexpression of TIF1g or Smad4 inhibits binding of Smad2/3 to the other, and depletion of one augments the binding of Smad2/3 to the other. Smad4-deficient tumor cells form a high level of Smad2/3-TIF1g complex, whereas cells with a high endogenous Smad4:TIF1g ratio show a high ratio of Smad2/3-Smad4 over Smad2/3-TIF1g complexes in response to TGFb.
This ability to compete for Smad2/3 notwithstanding, our evidence argues against TIF1g acting primarily as a negative regulator of Smad4. Even under conditions in which TIF1g overexpression markedly decreased the level of endogenous Smad2/3-Smad4, TIF1g caused only a small decrease in Smad4-dependent gene responses. We have not been able to obtain evidence that TIF1g targets Smad4 for ubiquitination and degradation, as was recently proposed by others for the human and Xenopus proteins (Dupont et al., 2005) . We observed no decrease in the levels of endogenous or cotransfected Smad4 when TIF1g was overexpressed by transfection, and no increase in Smad4 upon RNAi-mediated TIF1g depletion. We detected an interaction between TIF1g and Smad4 under conditions of protein overexpression, but the level of this complex was very low compared to the level of Smad2/ 3-TIF1g complex on TGFb stimulation. The functional consequences of genetically depleting TIF1g or Smad4 in hematopoietic progenitor cells are also inconsistent with an anti-Smad4 role of TIF1g. It is possible that the previously reported inhibitory effect of TIF1g on TGFb signaling in Xenopus embryos (Dupont et al., 2005) involves an anti-Smad4 mechanism that is unique to that system.
Distinct Effector Roles of TIF1g and Smad4 in TGFb-Dependent Erythropoiesis
Based on sequence similarity, chromosomal location, and exon boundaries, human TIF1g is closely related to zebrafish moonshine (mon) (Ransom et al., 2004) , which was identified as a gene required for blood formation. Mutations in mon disrupt both embryonic and adult hematopoiesis, as mutant hemangioblasts fail to express hematopoietic transcription factors, and undergo apoptosis. All reported mon mutations truncate the middle region (Ransom et al., 2004) , which we show to be a Smad2/3 binding region that cannot be trimmed without loss of this function. As TGFb controls the proliferation and differentiation of hematopoietic progenitor cells (Ruscetti et al., 2005; Ohta et al., 1987) , and Smads are implicated in erythropoiesis (Davidson and Zon, 2000; Epperly et al., 2005; Larsson and Karlsson, 2005; Schmerer and Evans, 2003) , we investigated these intriguing links.
In human umbilical cord blood CD34 + cells, which are a significant source for allogeneic stem cell transplantation (Cohen and Nagler, 2004) , Smad2/3 and TIF1g stimulate erythroid differentiation in response to TGFb whereas Smad2/3 and Smad4 mediate the antiproliferative response. RNAi-mediated deletion of TIF1g interfered with the differentiative response of these cells to TGFb but had no effect on the antiproliferative response. In contrast, Smad4 depletion prevented the antiproliferative response to TGFb without preventing the differentiative response. Depletion of Smad2 and Smad3 inhibited both the differentiative response and the antiproliferative response. Our results also suggest the existence of TGFb-and Smad-independent inputs in the control of hematopoietic stem/ progenitor cell development by TIF1g ( Figure 7D ). Smad2/3-TIF1g complexes, like Smad2/3-Smad4, could influence cell behavior through transcriptional regulation. Other TIF1 proteins serve as scaffolds for the assembly of nuclear protein complexes via the RBCC protein interaction domain (Peng et al., 2002) . Comparative transcriptomic analyses are underway to identify TIF1g-dependent TGFb gene responses that may mediate erythroid differentiation. However, whether TIF1g is a general mediator of cell differentiation by the TGFb family is unknown. It should also be noted that the hematopoietic collapse of TIF1g-deficient zebrafish occurs without gross defects in earlier developmental events that are known to require extensive TGFb signaling (Ransom et al., 2004) .
TIF1g is on human chromosome 1p13, which is an active breakpoint for chromosomal abnormalities in cancer (Johansson et al., 1994; Ng et al., 1999; Sawyer et al., 2002) . Translocations resulting in a fusion of TIF1g and RET, which encodes a receptor tyrosine kinase, occur in childhood papillary thyroid carcinomas (Klugbauer and Rabes, 1999) . Thus, alterations in TIF1g-dependent differentiative functions might contribute to carcinogenesis. The present findings may also have implications for pancreatic cancers and other tumors that suffer loss of Smad4 while retaining TGFb receptors, Smad2/3, and TIF1g (Subramanian et al., 2004) . Smad4-defective cancer cells are proficient at forming Smad2/3-TIF1g complexes, which could participate in the pro-tumorigenic responsiveness of tumor cells to TGFb.
In sum, our results suggest that TIF1g associates with Smad2/3 to stimulate erythroid differentiation of hematopoietic stem/progenitor cells whereas Smad4 associates with Smad2/3 to inhibit the proliferation of these cells in response to TGFb. The widespread expression of TIF1g and the ability of different cell types to form Smad2/3-TIF1g complexes suggest that this complex may play other important roles in TGFb action.
EXPERIMENTAL PROCEDURES
Affinity Purification of HeLa Extracts and Protein Identification
For affinity purification, one liter of HeLa-S3 cells (about 560 million) from National Cell Culture Center was lysed by sonication in 2 ml of HKG lysis buffer (10 mM HEPES pH 7.9, 100 mM KCl, 10% Glycerol, 5 mM MgCl 2 , 10 mM NaF, 20 mM b-glycerolphosphate, 1 mM Na 3 VO 4 , 0.2% NP-40) supplemented with protease inhibitors cocktail (Roche), then precleared with 100 mg GST and centrifuged at 50,000 g for 30 min. The supernatants were incubated with glutathioneSepharose prebound with 50 mg proteins for 4 hr at 4ºC on a rotating platform. The bound proteins were eluted by the elution buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 2 mM DTT, 0.15% Sarcosyl) at room temperature for 10 min. The eluted proteins were subjected to SDS-PAGE and Coomassie blue staining. The bands were excised from the gel and proteins identified by peptide mass fingerprinting using matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry (MS).
Anti-TIF1g Antibodies
Purified N-terminal His 6 -tag TIF1g-M (456-887) and TIF1g-PB (888-1127) proteins of human TIF1g were used to immunize rabbits for antisera (Bethyl Labs), which were further affinity purified using columns packed with antigen-conjugated Sepharose following standard protocols.
Retroviral Transduction of CD34 + Cells
Human cord blood CD34 + cells were prestimulated for 48 hr in serumfree Quality Biological serum-free-60 (QBSF) medium (Quality Biological) supplemented with SCF (100 ng/ml) (Peprotech), FL (100 ng/ml) (Imclone), and TPO (100 ng/ml) (Peprotech). High-titer retroviral supernatants are applied immediately to the CD34 + cells on retronectincoated 6-well plates (Takara). Two consecutive transduction rounds were performed 8 hr apart in polybrene (4 mg/ml). Transduction rates of >30% were routinely obtained with CD34 + cells under these conditions. Transduced cells were allowed to recover for 48 hr with fresh medium and selected by FACS sorting.
Transfection of CD34 + Cells by Electroporation
One or two million CD34 + cells were resuspended in buffer provided in human CD34 cell nucleofector kit (Amaxa), mixed with the desired amount of plasmid DNA, and electroporated with U-08 program of nucleofector (Amaxa) as suggested by the manufacturer.
Colony-Forming Cell Assays
Colony-forming cell (CFC) assays were performed in triplicate in 35 mm plates using 1.2% methylcellulose (Dow Chemical), 30% FBS, 57.2 mM b-mercaptoethanol, 2 mM glutamine, 0.5 mM hemin (Sigma), 20 ng/ml IL-3 (Peprotech), 20 ng/ml SCF, and 6 U/ml EPO (Ortho Biotech). Colonies were scored 14 days after plating. Five colonies were plucked and pooled to cytospin and stain for Wright-Giemsa to determine the differentiation status of the cells, or all the colonies were resuspended and replated for secondary CFC assays.
Liquid Culture Assays for TGFb-Induced Growth Inhibition and Erythroid Differentiation Cytokine-driven liquid expansion cultures were performed with FACSsorted GFP-positive CD34 + cord blood cells (1.5 3 10 4 cells/ml) in QBSF serum-free medium, and 100 ng/ml SCF, FL, and TPO in the absence and presence of 80 pM TGFb. After 3 days in liquid expansion culture, cells were counted by trypan blue exclusion staining. Cytokine-driven liquid erythroid differentiation cultures were performed as described below based on whether transduction of retroviruses or transfection by electroporation were used to introduce desired genes into CD34 + cells. For transduction of retroviruses, CD34 + cells
were stimulated for 48 hr as described above and a cytokine cocktail of SCF (100 ng/ml) and EPO (6 U/ml) was added during transduction for 48 hr. After a total of 4 days of stimulation and transduction, cells were sorted and assayed for 3 days in SCF (100 ng/ml) and EPO (6 U/ ml). For transfection by electroporation, CD34 + cells were stimulated for 72 hr and a cytokine cocktail of IL-3 (100 ng/ml), SCF (100 ng/ml), and EPO (6 U/ml) was added during transfection for 48 hr. After a total of 5 days of stimulation and transfection, cells were sorted and assayed for 4 days in IL-3 (100 ng/ml), SCF (100 ng/ml), and EPO (6 U/ml).The erythroid differentiation status was determined by assessing cytospin preparations of the cultures stained with Wright-Giemsa and counting cells in different fields of view for a total of 500 to 600 cells.
Subsequently, absolute cell numbers were determined through counting by trypan blue dye exclusion staining.
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